Spontaneous reduction of prolactinoma post cabergoline withdrawal
نویسندگان
چکیده
منابع مشابه
Cabergoline Treatment in Invasive Giant Prolactinoma
Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive giant prolactinoma. Here, we report a case of invasive giant prolactinoma in a 52-year-old Saudi male with dramatic response to cabergoline tr...
متن کاملLong-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
BACKGROUND Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. OBJECTIVE The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking cabergoline for the treatment of prolactinoma and to explore any associations with the cumulative dose of drug used. DESIGN A cross-sectional echocard...
متن کاملMassive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
In 1970 a 20 year old woman presented with a pituitary chromophobe adenoma for which she underwent transfrontal pituitary surgery. In 1978 she had to be reoperated on because of local tumour recurrence, resulting in hypopituitarism. Bromocriptine (5 mg/day) was given for 15 years, but the plasma prolactin levels remained elevated. In 2000 the patient presented with signs and symptoms suggestive...
متن کاملEvaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma
OBJECTIVE The aim of the study was to determine whether atherosclerotic risk markers exist at the moment and after withdrawal of cabergoline (CAB) therapy in patients who had taken a suitable dose of CAB therapy for a suitable period of time before cessation of CAB. METHODS This study was designed as prospective cross-sectional. Out of a total of 115 patients with prolactinoma, 42 non-obese w...
متن کاملEffectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
OBJECTIVE To review our experience with cabergoline, a D2-selective dopamine agonist, for the treatment of giant prolactinomas. DESIGN A retrospective case series; descriptive statistics. METHODS The study group included 12 men aged 24-52 years (mean 39.2 years) treated for giant prolactinoma at our centers from 1997 to 2006. Cabergoline was started at a dose of 0.5 mg/three times a week an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Endocrinology and Metabolism
سال: 2012
ISSN: 2230-8210
DOI: 10.4103/2230-8210.100656